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Summary
Objective: To determine trabecular and subchondral bone metabolic changes in experimental canine osteoarthritis (OA).
Methods: OA was induced in 19 dogs by transection of the anterior cruciate ligament (ACL) of the right knee through a stab wound. Dogs were
sacriﬁced at 8 (nZ 7) and 12 weeks (nZ 12) after surgery. Non-operated normal dogs (nZ 6) were used as controls. After sacriﬁce, samples
were obtained from the weight-bearing area of medial tibial plateaus. Explants and cell cultures were prepared from subchondral and
trabecular bone. Osteocalcin (Oc), cellular alkaline phosphatase (ALPase), urokinase plasminogen-activator (uPA), prostaglandin E2 (PGE2),
metalloproteinase (MMP) and nitric oxide (NO) were measured using standard procedures.
Results: ALPase production was signiﬁcantly increased only at week 12 in subchondral and trabecular bone, while an increase in Oc was
noted at week 8. uPA and MMP activity were increased signiﬁcantly at week 12 in subchondral bone, while PGE2 levels were signiﬁcantly
higher in subchondral and trabecular bone at week 12 compared to normal. A decrease in NO production appeared late at week 12 in
trabecular bone, whereas NO levels from subchondral bone were signiﬁcantly increased compared to normal at week 8.
Discussion: Intense bone remodeling takes place in both subchondral and trabecular bone in the knee following ACL transection. This process
seems to occur around week 12, although Oc and NO appeared to be involved earlier at 8 weeks. These results suggest that not only
subchondral but also trabecular bone metabolism is altered in this OA model.
ª 2005 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Osteoarthritis (OA) is a debilitating disease affecting a great
portion of the population aged 60 or more1. Although its
exact pathophysiology is incompletely understood, struc-
tural changes include progressive articular cartilage degra-
dation, osteophyte formation, subchondral bone sclerosis
and synovial inﬂammation. Initially believed to be a cartilage
disease, evidence points toward subchondral bone in-
volvement, as ﬁrst suggested by Radin et al.2 in 1970.
Imaging studies have shown that bone metabolism
changes occur before cartilage damage3,4 and recent
studies have reported changes in cellular activity of
subchondral bone with a possible role in the initiation and/
or progression of the disease5e8. OA can be understood
only if the relationship between mechanics and biology is
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2004.310fully appreciated. There is no in vivo early marker of
cartilage breakdown other than destructive structural
studies. Nevertheless, the fact that bone metabolism is
altered at least at a very early stage of the disease when
cartilage lesions are difﬁcult to identify remains strong
evidence on the importance of bone to OA pathophysiology.
Studies that looked at the morphology and metabolism of
subchondral bone in the early phase of the disease have, in
general, identiﬁed a remodeling process that primarily
favors bone resorption9.
Osteoarthritic subchondral bone exhibits an altered
metabolism when compared to normal bone based on the
levels of pro-inﬂammatory mediators produced10,11. Mod-
iﬁcations in alkaline phosphatase (ALPase) and osteocalcin
(Oc) levels in OA subchondral bone have already been
described implying that osteoblasts (Ob) from this pathol-
ogy have a higher metabolic proﬁle. These cells, however,
are laying down less mineralized matrix which results in an
impaired functional quality of osteoarthritic bone compared
to normal individuals12,13. Anomalies in the urokinase
plasminogen-activator (uPA) activity, which is important in
bone remodeling, and abnormal levels of prostaglandin E2
(PGE2), are also described in osteoarthritic subchondral
bone5,11,14,15. Many studies have reported the importance
of nitric oxide (NO) and metalloproteinases (MMP) in OA
initiation/progression. NO appears to have a dual effect on
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lysis depending on its concentration16e19. NO also plays
a role in cartilage degradation20. Concurrently, the MMP
family is involved in cartilage destruction21,22 and the
presence of stromelysin has already been described in
bone23.
Studies of initiation and early progression of OA are
difﬁcult in humans and the use of experimental OA models
has allowed important insights into the pathophysiology of
this disease and a chronological evaluation of events24e27.
In particular, the canine anterior cruciate ligament (ACL)-
deﬁcient model (Pond-Nuki dog model) has been shown to
reliably reproduce changes found in human osteoarthritic
bone14,25,28e33. Radin and Rose34 proposed that in certain
models of OA, alterations of the bony bed occur before the
cartilage changes and suggest that this can occur in clinical
conditions. Based on metabolic alterations reported in
osteoarthritic subchondral bone locally6e8,10 along with
previously reported generalized bone metabolism altera-
tions3,4,6,35,36, we chose an experimental dog OA model to
assess the metabolic events in subchondral and trabecular
bone in early-stage OA. ALPase, Oc, uPA, NO, PGE2 and
MMP presence in bone were evaluated to determine the
metabolic activity of subchondral and trabecular bone using
the Pond-Nuki dog model.
The aims of the present study were to further characterize
the metabolic events that take place in the subchondral and
trabecular bone in the early phases of experimental dog
OA. More speciﬁcally, explore some of the markers and
metabolic modulators involved in bone remodeling such as
Oc, cellular ALPase, uPA, PGE2, MMP and NO.
Material and methods
EXPERIMENTAL GROUPS
A total of 25 skeletally mature crossbred dogs (2e3 years
old, 22e27 kg each) were used in this study. They were all
conditioned and manipulated according to the Canadian
Animal Protection guidelines. Brieﬂy, OA was induced in 19
dogs by surgical sectioning of the ACL of the right knee
through a stab wound, as previously described31e33. These
surgeries were scheduled at different time points so as to
provide for a simultaneous end of the study. After surgery,
the dogs were kept in animal care facilities for 1 week then
sent to a housing farm. Dogs were housed in a large pen
where they could exercise ad libitum under supervision to
ensure that they were bearing weight on the operated knee.
These experimental conditions have been shown to
induce reproducible osteoarthritic lesions in this mod-
el28,31,33. Dogs were sacriﬁced at 8 weeks (nZ 7) and 12
weeks (nZ 12) after surgery by an intravenous barbiturate
overdose injection. Non-operated normal dogs (nZ 6) were
used as a baseline control and were submitted to the same
housing and exercise conditions described above. This
study was approved and supervised by the local Institu-
tional Committee for Animal Protection.
SPECIMEN SELECTION
Dogs developed OA in the operated right knee as
previously reported by our group14,25,28,31. Samples were
obtained from the weight-bearing surface of medial tibial
plateaus and were isolated under sterile conditions, as
previously described10,14. Bone plugs (20 mm2) from
normal and OA dogs were obtained from the weight-bearingportion of the medial tibial plateau14,25,28. No marginal
cortical bone was included. The overlying articular cartilage
was ﬁrst removed using a scalpel and a rasp, and
subchondral bone explants 500e1000-mm-thick were dis-
sected from the metaphyseal trabecular bone using a re-
ciprocating saw and a rasp. Metaphyseal trabecular bone
samples were then taken 1 cm deep from the subchondral
bone using a reciprocating saw using a technique adapted
from our previous studies14,25,28. Subchondral bone and
trabecular bone explants and primary cell cultures were
prepared as follows. All cultures were prepared within 2 h
following sacriﬁce.
PREPARATION OF BONE EXPLANTS AND PRIMARY
OB-LIKE CELL CULTURES
Bone explant cultures were used to study several
modulators implicated in metabolic regulation in this model.
Bone explants better represent the in vivo situation at the
time of sacriﬁce than isolated cell cultures, and account for
the interaction of different cell populations and their
interaction in bone. However, levels of ALPase activity
and cellular Oc contents are best measured and are more
reliable when using cell cultures10,37,38. Oc can be readily
obtained in conditioned media from explants however;
ALPase is a membrane enzyme and therefore cannot be
measured in conditioned media. We would have to digest
the explants to perform such determinations, a situation that
could alter its activity. We therefore elected not to determine
them in our specimens and we opted for cell cultures rather
than explant cultures.
Brieﬂy, ex vivo bone explants were prepared using
200 mg (wet weight) samples. Explants were washed three
times by vortexing samples in serum-free Ham’s F-12/
Dulbecco’s modiﬁed Eagle’s medium (DMEM; Sigma,
St. Louis, MO). The explants were cultured in the serum-
free BGJ medium at 37(C in a humidiﬁed atmosphere with
5% O2/95% CO2. Culture media were recovered after
5 days of culture and stored at 80(C prior to assay39.
Primary cell cultures were prepared as previously
described37,40. Brieﬂy, when Ob reached conﬂuence
(4 weeks), they were split once at high density (50,000
cells/cm2) and placed in 24-well plates. After 2 days of
recovery, they were incubated with DMEMC 10% fetal
bovine serum albumin (FBS) and 2 days later with DMEM
(Sigma) containing 50 mg/ml ascorbic acid and 0.1% FBS.
Conditioning was performed for the last 2 days of culture, in
the presence or absence of 50 nM 1,25(OH)2D3 (1,25-
dihydroxyvitamin D), in DMEM, containing 2% charcoal-
stripped FBS. The medium was collected at the end of the
incubation and frozen at 80(C prior to assay. It was
previously demonstrated that cells obtained under these
culture conditions keep an Ob-like phenotype37,41,42. In
general, the conditions set for Ob culture are very stringent
and a greater than 95% Ob homogeneity has been shown
in previous studies37,40,42e44.
DETERMINATION OF CELLULAR ALPASE ACTIVITY
AND OC IN PRIMARY OB-LIKE CELLS
Cellular ALPase
Cellular ALPase activity was determined on the same
cells used for Oc, measured as the release of p-nitrophenol
hydrolyzed from p-nitrophenyl phosphate (12.5 mM ﬁnal
concentration) at 37(C for 30 min after solubilizing the cells
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aliquots14. Protein determination was performed by the
bicinchoninic acid method45.
Osteocalcin
Oc release was measured in conditioned Ham’s F-12/
DMEM (1:1) media (Sigma) prepared for the last 2 days of
culture of Ob-like cells. Nascent Oc was determined by
a speciﬁc dog Oc radioimmunoassay (Biomedical Technol-
ogies, Inc., Stoughton, MA). The assay is sensitive at
0.08e20 ng/ml, and 2% charcoal-treated FBS contains less
than 0.1 ng/ml Oc37.
DETERMINATION OF PGE2 AND NO LEVELS
IN BONE EXPLANTS
Culture medium from subchondral and trabecular bone
explants (200 mg wet weight per explant tested, 5 days of
culture) was used for the next assays.
PGE2 determination
The amount of PGE2 produced by the explants and
released into the medium was assessed by use of an
Enzyme Immunoassay Kit from Cayman Chemical (Ann
Arbor, MI). This assay is based on the competition between
PGE2 and PGE2eacetylcholinesterase conjugate (PGE2
tracer) for a limited amount of PGE2 monoclonal antibody.
The sensitivity was 9 pg/ml and the working range was
between 10 and 1000 pg/ml based on logarithmic trans-
formation. The reaction was measured on a micro-ELISA
Vmax photometer (Molecular Devices Corp., Menlo Park,
CA)14.
Measurement of nitrite
Nitrite was determined in explant culture medium, as
a stable end product of NO generated by the explanted cells.
Nitrite accounts for approximately 50% of the NO generated
in culture of explants. Brieﬂy, 200 ml of the Gries reagent
(1 Vol 1% sulphanilamide in 5% H3PO4 and 1 Vol 0.1%
naphthylethylenediamine dihydrochloride in H2O), freshly
prepared, was added to 200 ml of culture medium, mixed and
kept at room temperature for 30 min. Samples were then
centrifuged (12,000 rpm, 2 min) (Microfuge 12, Beckman Inc,
NY, USA), and the supernatant was read on a spectropho-
tometer (Beckman DU 640, Beckman Inc, NY, USA) at
550 nm. Results were ﬁt to a standard curve and the results
expressed in nmol/g of tissue wet weight20.
DETERMINATION OF uPA AND MMP ACTIVITY
IN BONE EXPLANTS
uPA activity
uPA activity was determined by the procedure of
Leprince et al.41. This assay determines the activity of
uPA via the hydrolysis of the speciﬁc substrate DL-Val-Leu-
Arg-p-nitroanilide (Sigma) that releases p-nitroaniline that
can be detected at 405 nm.
MMP activity assay
The MMP activity in the culture medium was measured
by the method of Chavira et al.46 using Azocoll (Calbio-
chem-Behring, San Diego, CA) as substrate. Brieﬂy, 100 mlof azocoll suspension was incubated under the following
conditions: (1) with 100 ml of culture medium in the
presence of 1 mM 4-aminophenylmercuric acetate (APMA)
and, (2) with a 100 mm aliquot of culture medium with 1 mM
APMA and 1,10-phenantroline, to serve as a blank. After
incubation (48 h, pH 6.2, 37(C), the solution was centri-
fuged (12,000 g for 15 min at 4(C) and the supernatant’s
optical density was determined by spectrophotometric
analysis at 520 nm. The MMP activity was expressed in
units per gram of tissue wet weight, in which 1 unit
corresponded to the hydrolysis of 1 mg of substrate/h at
37(C. The azocoll-digesting activity in the culture medium
was inhibited O90% by 1,10-phenanthroline31,32. Most but
not all of the enzymatic activity measured at pH 6.2 using
this method should correspond to stromelysin31,32,47. In
fact, stromelysin seems to be conﬁned to the acid pH
form48, but enzymatic activity at pH 6.2 also comes from
gelatinases such as MMP-2.
Statistical analysis
Results are expressed as the meanG S.E.M. Assays were
performed in triplicate. Statistical analysis was performed
using the two-tailed ManneWhitney U test. InStat 1.5 for
MacIntosh software was used to do all statistical analysis
(GraphPad Software Inc., San Diego, CA, USA). P values
less than 0.05 were considered signiﬁcant.
Results
ALPASE AND OC PRODUCTION
Basal levels of ALPase activity in subchondral bone and
trabecular bone Ob were not signiﬁcantly different through-
out the experiment. Moreover, levels of ALPase activity in
subchondral and trabecular Ob were not affected by
stimulation with 1,25(OH)2D3 in normal and operated knees
[Fig. 1(A,B)], a situation previously observed in dog Ob25.
Although OA changes typically start to appear macroscop-
ically in articular cartilage at 8 weeks in this model,
signiﬁcant differences in the levels of ALPase between
OA Ob and normal Ob could be found only at 12 weeks in
subchondral bone (control vs 12 weeks: 2.8-fold increase,
P! 0.05, 8 weeks vs 12 weeks: 2.5-fold increase,
P! 0.05) [Fig. 1(A)]. A similar proﬁle was observed when
comparing OA Ob and normal Ob in trabecular bone
(control vs 12 weeks: 5-fold increase, P! 0.01) [Fig. 1(B)].
In contrast to ALPase, Oc production by Ob was
increased by incubation with 1,25 (OH)2D3 in subchondral
bone (P% 0.05) [Fig. 2(A)], as previously reported7,25 and
in trabecular bone Ob (P% 0.05) [Fig. 2(B)]. In subchondral
bone, a signiﬁcant increase in Oc production at 8 weeks in
non-stimulated Ob and in 1,25(OH)2D3 stimulated OA Ob at
8 and 12 weeks was observed compared to normal (5-fold
increase; P! 0.02) [Fig. 2(A)]. Trabecular bone Ob showed
a signiﬁcant increase in the production of Oc at 8 and
12 weeks, with or without 1,25(OH)2D3 stimulation (control
vs 8 weeks: 2-fold increase, P! 0.05; control vs 12 weeks:
5-fold increase, P! 0.02) [Fig. 2(B)].
uPA ACTIVITY
In subchondral bone, a gradual increase in uPA activity
was seen up to 12 weeks, when it reached signiﬁcant
values (3.5-fold increase; P! 0.03; Fig. 3). Trabecular
bone uPA activity remained relatively constant during the 12
weeks of the experiment. Basal uPA activity in trabecular
313Osteoarthritis and Cartilage Vol. 13, No. 4bone explants remained high at all time points, the
difference not being signiﬁcant.
PGE2 PRODUCTION
Culture media from subchondral and trabecular bone
explant cultures were used to determine PGE2 levels in our
OA model (Fig. 4). In subchondral bone, there was
a signiﬁcant increase (13- and 10-fold increase from 0 to
12 weeks, P! 0.0001) in PGE2 production. In trabecular
bone explants, PGE2 production was also increased only at
12 weeks compared to control and 8 weeks (17- and 8-fold
increase, respectively; P! 0.01). There were no major
changes in PGE2 production from 0 to 8 weeks in trabecular
bone.
NO PRODUCTION
NO production in subchondral bone explant cultures
showed a signiﬁcant increase at 8 weeks (2.5-fold increase;
P! 0.005) followed by a 2.5-fold decrease from 8 to 12
weeks (P! 0.002) back to normal values (Fig. 5). In-
terestingly, trabecular bone showed a continuous decrease
in NO contents from 0 to 12 weeks (1.5-fold decrease at
8 weeks; 3-fold decrease from 8 to 12 weeks, P! 0.04;
for a total 4-fold decrease, P! 0.01) (Fig. 5).
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Fig. 1. ALPase production by Ob from experimental OA dogs. Bone
samples were retrieved from control dogs (nZ 6), from experi-
mental OA dogs at 8 weeks (nZ 7) and 12 weeks (nZ 12) after
ACL section and cultured for 6 weeks to extract the Ob.
Subchondral Ob (A) and trabecular Ob (B) were then plated for
48 h with or without 50 nM 1,25(OH)2D3. Cells were then
solubilized for evaluation of ALPase production. Results are
expressed as meanG S.E.M. P values% 0.05 were considered
signiﬁcant. (A: *P% 0.05, 12 week group vs control; B: P% 0.01,
12 week group vs control). SB, subchondral bone; TB, trabecular
bone.MMP ACTIVITY
MMP activity was measured in explants from both
subchondral and trabecular bone (Fig. 6). In subchondral
bone, the differences in activity of MMP showed a trend to
less activity at 8 weeks (P! 0.06) followed by a 3.3-fold
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Fig. 2. Oc production by Ob from experimental OA dogs. Bone
explants were retrieved from control dogs (nZ 6), from experi-
mental OA dogs at 8 weeks (nZ 7) and 12 weeks (nZ 12) after
ACL section and cultured for 6 weeks to extract the Ob. Ob were
then plated for 48 h with or without 50 nM 1,25(OH)2D3 and the
supernatant recovered for evaluation of Oc production. Results are
expressed as meanG S.E.M. P values% 0.05 were considered
signiﬁcant. (A: *P% 0.02, at 8 and 12 weeks vs control, with or
without 1,25(OH)2D3 stimulation; B: P% 0.05 at 8 weeks, P% 0.02
at 12 weeks, with or without 1,25(OH)2D3 stimulation). SB,
subchondral bone; TB, trabecular bone.
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Fig. 3. uPA activity by bone explants from experimental OA dogs.
Bone explants were retrieved from control dogs (nZ 6), from
experimental OA dogs at 8 weeks (nZ 7) and 12 weeks (nZ 12)
and cultured for 5 days. Culture medium was analyzed for uPA
activity. Results are expressed as meanG S.E.M. P values% 0.05
were considered signiﬁcant. (Subchondral bone: *P% 0.03 at 12
weeks vs control.) SB, subchondral bone; TB, trabecular bone.
314 P. Lavigne et al.: Bone metabolism in canine osteoarthritisincrease from 8 to 12 weeks (P! 0.05), for a net increase
of 1.6-fold from 0 to 12 weeks. These variations in MMP
activity in subchondral bone are in contrast to what can be
observed in trabecular bone, where no variation was
observed.
Discussion
In this study, we evaluated the changes in the metabolic
proﬁle of bone after experimentally inducing OA in a canine
model. Our results conﬁrm previous evidence that trabec-
ular bone metabolism is altered in OA compared to a normal
control. Using the contralateral non-operated knee from OA
dogs as a control could introduce potential ﬂaws in the
analysis of the results, since it also presents metabolic
changes in this OA model23. Although we have designed
the explants using a standard 200 mg wet weight sampling,
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Fig. 4. PGE2 production in bone explants from experimental OA
dogs. Bone explants were retrieved from control dogs (nZ 6), from
experimental OA dogs at 8 weeks (nZ 7) and 12 weeks (nZ 12)
and cultured for 5 days. Culture medium was analyzed for PGE2
contents. Results are expressed as meanG S.E.M. P values% 0.05
were considered signiﬁcant. (Subchondral bone (SB): *P% 0.0001,
12 weeks vs control; Trabecular bone (TB): **P% 0.0001, 12 weeks
vs control.)
0
100
200
300
SB
TB
*
**
0 8 12 0 8 12
Weeks
C
o
n
c
e
n
t
r
a
t
i
o
n
 
(
n
m
o
l
 
N
O
/
g
.
w
w
)
Fig. 5. NO production in bone explants from experimental OA dogs.
Bone explants were retrieved from control dogs (nZ 6), from
experimental OA dogs at 8 weeks (nZ 7) and 12 weeks (nZ 12)
and cultured for 5 days. Culture medium was analyzed for the
presence of nitrite using the Greis reaction. Results are expressed
as meanG S.E.M. P values% 0.05 were considered signiﬁcant.
(Subchondral bone (SB): *P% 0.005, 8 weeks vs control;
Trabecular bone (TB): **P% 0.01, 12 weeks vs control.)we cannot state that cell numbers between subchondral
bone and trabecular bone are equal. Therefore, any direct
comparison in the results between the two groups has to be
carefully analyzed, as the results are normalized to sample
weight and not to cell count. Notwithstanding, these ﬁndings
suggest that changes in OA are not conﬁned only to
periarticular cells, but also involve trabecular bone away
from the diseased joint. Brandt et al.29 have reported an
increased bone uptake in the unstable knee in this OA
model using bone scans. Other studies by Myers et al.49 in
the ACL-deﬁcient dog model at 12 weeks post-surgery have
also reported quantitative data on bone formation and
resorption in the cancelous subchondral bone. Given the
higher bone turnover of trabecular bone in OA, our results
on increased levels of ALPase and Oc levels in this model
are not surprising.
Our results indicate higher levels of ALPase and Oc in
osteoarthritic bone compared to normal bone. These results
concur with those reported by Hilal et al.10, where they have
shown a similar increase in production of those mediators in
human OA Ob compared to normal Ob. This difference in
metabolism could translate into a less mineralized matrix
deposition and could account for the higher osteoid volume
in osteoarthritic bone reported by other groups50,51. It is
interesting to note that ALPase levels were only increased
at 12 weeks. Oc levels were already higher at 8 weeks but
showed a striking increase at 12 weeks. Recent data by
Ivaska et al.52 suggested that several molecular forms of Oc
are released from the bone matrix during bone resorption
both as intact molecules and fragments. Since we
measured only the intact form of Oc, there might be an
underestimation on the total content of Oc present in the
culture medium in this study. This could mean that the effect
of ALPase on osteoarthritic bone is not an early event in the
progression of the disease in this canine model. It could
explain, at least in part, why OA is initially characterized by
a decrease in bone density later followed by abnormal bone
deposition24,30, which correlates to Oc and ALPase in-
creasing levels in bone. It has been reported by Dedrick
et al.24,30 and Pelletier et al.28 that osteoarthritic bone
exhibits initial porosity (initial 2e3 months) in an exper-
imental canine OA model, followed by gradual subchondral
plate stiffening and cancelous osteoarthritic bone thinning
0
250
500
750
1000
1250
SB
TB
*
0 8 12 0 8 12
Weeks
C
o
n
c
e
n
t
r
a
t
i
o
n
 
(
U
/
g
.
w
w
/
5
 
d
a
y
s
)
Fig. 6. MMP activity in bone explants from experimental OA dogs.
Bone explants were retrieved from control dogs (nZ 6), from
experimental OA dogs at 8 weeks (nZ 7) and 12 weeks (nZ 12)
and cultured for 5 days. Culture medium was analyzed for MMP
activity using the azocoll-substrate digestion technique. Results are
expressed as meanG S.E.M. P values% 0.05 were considered
signiﬁcant. (Subchondral bone: *P! 0.05, 12 weeks vs 8 weeks)
SB, subchondral bone; TB, trabecular bone.
315Osteoarthritis and Cartilage Vol. 13, No. 4(between 18 and 54 months)24,30. Given the levels of
ALPase and Oc in subchondral and trabecular bone in our
study, changes in bone density must begin after 12 weeks
or involve other mediators in order to take place. This is in
accordance to Boyd et al.53 that trabecular bone is
signiﬁcantly altered by 12 weeks in this OA model.
Moreover, lower levels of PGE2 should support bone
formation while higher levels should allow for a more
intense resorption54. In our model, levels of PGE2 remained
low for the ﬁrst 8 weeks and then increased signiﬁcantly at
12 weeks. This observation could also explain the thinning
in trabecular bone described in the literature at 12
weeks24,28. On the other hand, it cannot account for the
early osteopenia generally observed in this model, which is
followed by late subchondral bone stiffening28. There is also
evidence in the literature of possible disuse osteopenia at
this post-operative interval due to decreased load bearing
by the canine ACL-deﬁcient knee in the ﬁrst weeks after
surgery53. While the increased mechanical forces acting on
bone from an unstable knee can also account for the
induction of PGE2
55 and COX-256 and result in stimulation
of bone formation57,58, PGE2 can stimulate the production
of interleukin-6, a bone-resorbing cytokine42,59,60 and
insulin-like growth factor-I (IGF-I), an anabolic growth factor
for bone10,14,60. Previous observations that the modiﬁca-
tions of uPA are directly related to PGE2 synthesis
14
suggest a possible link between uPA and PGE2. uPA
activity raised to a signiﬁcant level in subchondral bone at
week 12 in this study. It is interesting to note that abnormal
bone remodeling in OA may be linked to altered IGF-I levels
in osteoarthritic bone and Ob linked to the uPA/plasmin
system5. However, this will have to be tested directly.
NO has a dual action on Ob function: low levels stimulate
bone anabolism, while higher levels induce catabo-
lism18,19,37. Based on these assumptions, it would be
tempting to assume that trabecular bone could be engaged
in anabolic remodeling that was ongoing from baseline to
week 12. Subchondral bone, on the other hand, seems to
be engaged on a catabolic pathway from baseline to week
8. This is in accordance with previous work that described
softening of the subchondral plate at early stages of OA28.
Anabolic remodeling via NO mediation seems to be
resuming by week 12, as illustrated by the decreased NO
content.
MMP activity levels were actually lower at 8 weeks in
subchondral bone. There is a signiﬁcant increase in MMP
activity from week 8 to week 12 (Fig. 6). Present ﬁndings of
increased levels of MMP in subchondral bone in this model
at week 12 compared to week 8, combined with the
increased bone turnover illustrated by higher uPA activity in
OA, suggest that the action of MMP in other osteoarthritic
tissues at 12 weeks might come, at least in part, from bone
and not solely from other joint tissues such as the synovial
membrane22. A direct relationship has already been
reported between licofelone-mediated levels of uPA,
IGF-I, or PGE2 in subchondral Ob and the reduction in the
size of lesions on tibial plateaus in this dog model14.
There is still speculation as to whether the abnormal
subchondral bone morphology and biochemistry are linked
to the development/progression of cartilage damage. Some
studies have reported that the subchondral bone changes
preceded the cartilage lesions and could be responsible for
the evolution of cartilage lesions34,50. Other studies have
reported that subchondral bone changes happen simulta-
neously or even follow cartilage changes and, therefore,
could only be a secondary phenomenon to cartilage
degradation26,61,62. We designed this study essentially tobetter understand subchondral bone and trabecular bone
metabolism in the ACL-deﬁcient dog model. We wanted to
answer the question whether metabolic changes in sub-
chondral bone and trabecular bone would progress over
time (from time zero to 12 weeks after surgery) in this dog
model. Cartilage lesions in this study presented typical
macroscopic size and grade severity at 8 and 12 weeks, as
we have previously described31e33. It would’ve been
appealing to correlate typical cartilage lesions in this model
with bone metabolism changes observed in this study.
Technically, isolating subchondral bone plugs scrapped
free of any cartilage or trabecular bone attached to it made it
impossible for us to evaluate articular cartilage microscop-
ically. A further study with a larger number of animals is
needed to answer this research question. Correlations
between the severity of articular cartilage lesions and bone
metabolism in OA are presently under way in our laboratory
to further understand the exact implications of bone
metabolism in OA.
In conclusion, this study indicates that intense bone
remodeling takes place simultaneously in subchondral and
trabecular bone in this experimental OA model. This is in
agreement with Burr and Schafﬂer63 that bone changes
precede cartilage ﬁbrillation temporally, and are associated
spatially within a single joint. ALPase, uPA, MMP and PGE2
appear to be late mediators in this process while NO and Oc
levels show an earlier increase in osteoarthritic subchondral
bone. This altered metabolism provides strong indication for
a more important role of bone in OA pathophysiology.
Changes in the subchondral cortical bone may accelerate
progression of pre-existing disease, but the combined
effects of increased subchondral bone turnover and greater
subchondral bone volume are not at all clear. As recently
suggested by Burr64, the efﬁcacy of bone anti-resorptive
therapies for OA will depend upon whether the increased
structural stiffness of the subchondral mineralized tissues
predisposes the cartilage to deteriorate, whether the
increased bone turnover that occurs in OA is itself
a causative factor, or whether the lower tissue elastic
modulus offsets the increased structural stiffness of the
subchondral plate in an attempt to protect the cartilage from
damage.
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